Advertisement


Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial

2017 ESMO Congress

Advertisement

Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).



Related Videos

Breast Cancer

Judy E. Garber, MD, MPH, on Triple-Negative Breast Cancer: An Update

Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, offers expert perspectives on the role of PARP inhibitors in treating triple-negative breast cancer.

Issues in Oncology

Bonnie S. Glisson, MD, on HPV-16+ Cancer: Study Results

Bonnie S. Glisson, MD, of The University of Texas MD Anderson Cancer Center, discusses a clinical trial on the combination of ISA101, an HPV-16 vaccine, and nivolumab for patients with incurable HPV-16+ cancer (Abstract 1136O).

Gynecologic Cancers

Simone Koole, MD, on Ovarian Cancer: Results of the OVHIPEC Trial

Simone Koole, MD (and a PhD candidate), of the Netherlands Cancer Institute, discusses phase III findings on health-related quality of life after hyperthermic intraperitoneal chemotherapy for stage III ovarian cancer.

Gynecologic Cancers

Domenica Lorusso, MD, PhD, on Cervical Cancer: Results From a Trial on Treatment Regimens

Domenica Lorusso, MD, PhD, of the National Cancer Institute of Milan, discusses neoadjuvant chemotherapy followed by surgery vs concurrent cisplatin and radiation therapy in patients with stage IB2 to IIB squamous carcinoma of the cervix (Abstract 928O_PR).

Breast Cancer

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Abstract LBA14).

Advertisement

Advertisement




Advertisement